JP2024059791A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024059791A5 JP2024059791A5 JP2024025175A JP2024025175A JP2024059791A5 JP 2024059791 A5 JP2024059791 A5 JP 2024059791A5 JP 2024025175 A JP2024025175 A JP 2024025175A JP 2024025175 A JP2024025175 A JP 2024025175A JP 2024059791 A5 JP2024059791 A5 JP 2024059791A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025279839A JP2026053563A (ja) | 2018-12-11 | 2025-12-24 | 補体関連疾患のための融合タンパク質構築物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862778014P | 2018-12-11 | 2018-12-11 | |
| US62/778,014 | 2018-12-11 | ||
| JP2021533356A JP7444886B2 (ja) | 2018-12-11 | 2019-12-11 | 補体関連疾患のための融合タンパク質構築物 |
| PCT/US2019/065741 WO2020123662A2 (en) | 2018-12-11 | 2019-12-11 | Fusion protein constructs for complement associated disease |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021533356A Division JP7444886B2 (ja) | 2018-12-11 | 2019-12-11 | 補体関連疾患のための融合タンパク質構築物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025279839A Division JP2026053563A (ja) | 2018-12-11 | 2025-12-24 | 補体関連疾患のための融合タンパク質構築物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024059791A JP2024059791A (ja) | 2024-05-01 |
| JP2024059791A5 true JP2024059791A5 (https=) | 2025-03-17 |
| JP7811315B2 JP7811315B2 (ja) | 2026-02-05 |
Family
ID=71076704
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021533356A Active JP7444886B2 (ja) | 2018-12-11 | 2019-12-11 | 補体関連疾患のための融合タンパク質構築物 |
| JP2024025175A Active JP7811315B2 (ja) | 2018-12-11 | 2024-02-22 | 補体関連疾患のための融合タンパク質構築物 |
| JP2025279839A Pending JP2026053563A (ja) | 2018-12-11 | 2025-12-24 | 補体関連疾患のための融合タンパク質構築物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021533356A Active JP7444886B2 (ja) | 2018-12-11 | 2019-12-11 | 補体関連疾患のための融合タンパク質構築物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025279839A Pending JP2026053563A (ja) | 2018-12-11 | 2025-12-24 | 補体関連疾患のための融合タンパク質構築物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240301043A1 (https=) |
| EP (1) | EP3893916A4 (https=) |
| JP (3) | JP7444886B2 (https=) |
| KR (2) | KR20250021629A (https=) |
| CN (1) | CN113660944A (https=) |
| AU (2) | AU2019398214C1 (https=) |
| IL (1) | IL283841A (https=) |
| MA (1) | MA54468A (https=) |
| MX (1) | MX2021006930A (https=) |
| MY (1) | MY209796A (https=) |
| PH (1) | PH12021551398A1 (https=) |
| SG (1) | SG11202106073QA (https=) |
| WO (1) | WO2020123662A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018075783A2 (en) * | 2016-10-20 | 2018-04-26 | President And Fellows Of Harvard College | In vitro and cell based assays for measuring the activity of botulinum neurotoxins |
| KR20220019806A (ko) * | 2019-06-12 | 2022-02-17 | 씨에스엘 이노베이션 피티와이 엘티디 | 가용성 보체 수용체 1형 변이체 접합체 및 이의 용도 |
| CA3182800A1 (en) | 2020-06-14 | 2021-12-23 | Vertex Pharmaceuticals Inc. | Complement factor i-related compositions and methods |
| CN114778418B (zh) * | 2022-06-17 | 2022-09-27 | 深圳安侣医学科技有限公司 | 基于显微放大数字图像的血红蛋白分析方法及系统 |
| KR20250057830A (ko) * | 2022-08-30 | 2025-04-29 | 롱바이오 파마 (수조우) 컴퍼니 리미티드 | 항-인간 보체 c5 항체 및 이의 융합 단백질 |
| WO2024099320A1 (zh) * | 2022-11-10 | 2024-05-16 | 天辰生物医药(苏州)有限公司 | 补体抑制杂合蛋白突变体及其抗体融合蛋白 |
| CN118373913B (zh) * | 2024-05-08 | 2024-11-01 | 上海百英生物科技股份有限公司 | 一种抗人Tim-3单克隆抗体及其制备方法 |
| CN118878672A (zh) * | 2024-08-01 | 2024-11-01 | 河北康立德生物科技有限公司 | 一种抗曲霉半乳甘露聚糖单克隆抗体、试剂盒及其应用 |
| CN119638823A (zh) * | 2024-12-10 | 2025-03-18 | 中国医学科学院病原生物学研究所 | 检测a35r蛋白的单克隆抗体及其应用 |
| CN119431565B (zh) * | 2025-01-10 | 2025-04-08 | 成都迈科康生物科技有限公司 | 一种抗hpv16型e6蛋白和e7蛋白的抗体、检测产品及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| EP1284752A4 (en) * | 2000-04-26 | 2004-08-18 | Elusys Therapeutics Inc | BISPECIFIC MOLECULES AND USES THEREOF |
| AU2002361106B2 (en) * | 2001-12-28 | 2007-06-07 | Kyowa Hakko Kirin Co., Ltd. | Remedies for arthritis |
| WO2005063815A2 (en) * | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| WO2006042252A2 (en) * | 2004-10-08 | 2006-04-20 | Potentia Pharmeceuticals, Inc. | Viral complement control proteins for eye disorders |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| SG186397A1 (en) * | 2010-06-22 | 2013-01-30 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3 |
| US8940490B2 (en) | 2010-11-29 | 2015-01-27 | Novelmed Therapeutics, Inc. | Neoantibodies for diagnosing tissue injury |
| JP2015535212A (ja) | 2012-08-17 | 2015-12-10 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト | 補体活性化を検出するための組成物および方法 |
| HK1218300A1 (zh) * | 2013-01-23 | 2017-02-10 | Musc Foundation For Research Development | 基於天然抗體的靶向結構體及其應用 |
| CA2930665A1 (en) * | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| US10035848B2 (en) * | 2014-01-08 | 2018-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody targeting cell surface deposited complement protein C3d and use thereof |
| MA39819A (fr) * | 2014-04-01 | 2017-02-08 | Rubius Therapeutics Inc | Méthodes et compositions d'immunomodulation |
| WO2015187992A2 (en) * | 2014-06-05 | 2015-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Map44 polypeptides and constructs based on natural antibodies and uses thereof |
| CN120988137A (zh) * | 2015-01-23 | 2025-11-21 | 赛诺菲 | 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体 |
-
2019
- 2019-12-11 EP EP19895581.7A patent/EP3893916A4/en active Pending
- 2019-12-11 SG SG11202106073QA patent/SG11202106073QA/en unknown
- 2019-12-11 KR KR1020257003118A patent/KR20250021629A/ko active Pending
- 2019-12-11 JP JP2021533356A patent/JP7444886B2/ja active Active
- 2019-12-11 MX MX2021006930A patent/MX2021006930A/es unknown
- 2019-12-11 CN CN201980091627.3A patent/CN113660944A/zh active Pending
- 2019-12-11 MY MYPI2021003245A patent/MY209796A/en unknown
- 2019-12-11 KR KR1020217021586A patent/KR102762828B1/ko active Active
- 2019-12-11 WO PCT/US2019/065741 patent/WO2020123662A2/en not_active Ceased
- 2019-12-11 PH PH1/2021/551398A patent/PH12021551398A1/en unknown
- 2019-12-11 MA MA054468A patent/MA54468A/fr unknown
- 2019-12-11 AU AU2019398214A patent/AU2019398214C1/en active Active
-
2021
- 2021-06-09 IL IL283841A patent/IL283841A/en unknown
-
2023
- 2023-12-15 US US18/542,100 patent/US20240301043A1/en active Pending
-
2024
- 2024-02-21 AU AU2024201109A patent/AU2024201109A1/en active Pending
- 2024-02-22 JP JP2024025175A patent/JP7811315B2/ja active Active
-
2025
- 2025-12-24 JP JP2025279839A patent/JP2026053563A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024059791A5 (https=) | ||
| US11879008B2 (en) | Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulator | |
| JP7773981B2 (ja) | 新型ポリペプチド複合物 | |
| JP6669722B2 (ja) | Ｃｄ３結合ドメイン | |
| JP2022512234A5 (https=) | ||
| JP6608702B2 (ja) | 補体関連疾患の予防及び治療のためのｃ５抗体及び方法 | |
| US20240301043A1 (en) | METHODS OF TREATING COMPLEMENT MEDIATED DISEASES WITH FUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND A COMPLEMENT MODULATOR | |
| JP2023123726A5 (https=) | ||
| JP2023134618A5 (https=) | ||
| CN111936514A (zh) | 多价抗体 | |
| US11041019B2 (en) | Anti human annexin A1 antibody | |
| JP2024532485A5 (https=) | ||
| TW201107345A (en) | Immunoglobulins | |
| CN117940460A (zh) | 双特异性抗原结合分子及其应用 | |
| JP2025517360A (ja) | トランスフェリン受容体結合ドメイン及びそれを含むタンパク質 | |
| CN116162161A (zh) | 一种抗il-6r的单域抗体及其用途 | |
| JP2023533504A5 (https=) | ||
| RU2824402C2 (ru) | Конструкции слитого белка для заболевания, связанного с комплементом | |
| CN120682353B (zh) | 一种特异性结合EsxB的单克隆抗体及其治疗试剂 | |
| CA3123004C (en) | Fusion protein constructs for complement associated disease | |
| CN118459582A (zh) | 一种抗焦谷氨酸修饰的β淀粉样蛋白抗体及其用途 | |
| JP2024545741A5 (https=) | ||
| CN118401253A (zh) | 备解素结合蛋白及其用途 | |
| WO2026037352A1 (zh) | 同时结合VEGF及Ang-2的Fc融合蛋白及其用途 | |
| JP2026506240A (ja) | Ｍｕｃ１及びｃｄ１６ａ抗体ならびに使用方法 |